Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODiXaHip: Rivaroxaban for VTE Prevention in Total Hip Replacement
NCT00839826Phase 2Completed
- Sponsor
- Bayer
- Start
- Dec 2002
- Primary completion
- Nov 2003
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of rivaroxaban in venous thromboembolism (VTE), sponsored by Bayer. Started Dec 2002; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00839826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00839826.